A
691.40
-1.43 (-0.21%)
| Previous Close | 692.83 |
| Open | 695.32 |
| Volume | 418,799 |
| Avg. Volume (3M) | 363,113 |
| Market Cap | 42,910,281,728 |
| Price / Earnings (TTM) | 35.33 |
| Price / Earnings (Forward) | 25.13 |
| Price / Sales | 10.56 |
| Price / Book | 5.61 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | argenx SE | Bearish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2025 | 461,854 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,247.00 (Wells Fargo, 80.36%) | Buy |
| Median | 1,000.00 (44.63%) | |
| Low | 867.00 (Baird, 25.40%) | Hold |
| Average | 1,014.33 (46.71%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 770.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 09 Mar 2026 | 1,000.00 (44.63%) | Buy | 740.40 |
| 14 Jan 2026 | 1,000.00 (44.63%) | Buy | 799.33 | |
| Baird | 27 Feb 2026 | 867.00 (25.40%) | Hold | 766.92 |
| Citizens | 27 Feb 2026 | 944.00 (36.53%) | Buy | 766.92 |
| Guggenheim | 27 Feb 2026 | 1,120.00 (61.99%) | Buy | 766.92 |
| HC Wainwright & Co. | 27 Feb 2026 | 940.00 (35.96%) | Buy | 766.92 |
| RBC Capital | 27 Feb 2026 | 890.00 (28.72%) | Buy | 766.92 |
| Wells Fargo | 27 Feb 2026 | 1,247.00 (80.36%) | Buy | 766.92 |
| 20 Jan 2026 | 1,317.00 (90.48%) | Buy | 809.64 | |
| Citigroup | 08 Jan 2026 | 1,091.00 (57.80%) | Buy | 795.57 |
| Truist Securities | 08 Jan 2026 | 1,030.00 (48.97%) | Buy | 795.57 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG |
| 12 Jan 2026 | Announcement | argenx Highlights 2026 Strategic Priorities |
| 06 Jan 2026 | Announcement | argenx to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Announcement | argenx Announces Leadership Transition Marking Next Evolution of Growth |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |